



JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015,
Haryana (India)

Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com
CIN NO. L74899DL1978PLC009181

March 8, 2024

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---	--

Subject: Press Release - Jagsonpal Pharmaceuticals launches QueeZy-ER®

Dear Sir/ Madam,

In terms of regulation 30 of the SEBI (LODR) Regulations, 2015, please find enclosed herewith a copy of the Press Release issued by the Company titled “**Jagsonpal Pharmaceuticals launches QueeZy-ER®**”.

We request you to take the above on record.

Thanking you,

For **Jagsonpal Pharmaceuticals Limited**

Abhishek Joshi
Company Secretary & Compliance Officer

Encl.: A/a



Jagsonpal Pharmaceuticals launches QueeZy-ER®

A Breakthrough Therapy for morning sickness during Pregnancy

Gurugram, March 8, 2024: Jagsonpal Pharmaceuticals Limited, a leading company operating in women healthcare segment today announced the launch of QueeZy-ER® providing relief from Nausea and Vomiting in Pregnancy (NVP).

The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation. The product comes with a tablet-in-tablet technology, which allows dispersal of uniform dosage at two different time-periods from the same dose, thereby allowing for 24-hour benefit to the patient. This allows for a single dose as against the conventional requirement of up to 3-4 tablets a day.

Further, the overall therapy cost per day is lower as compared to conventional pills.

The combination of Doxylamine succinate 20mg and Pyridoxine hydrochloride 20mg is the only USFDA approved combination for NVP treatment.

Key benefits of Queezy-ER®

- Extended-Release: Unique dual-release formulation for immediate and prolonged relief, reducing the need for frequent dosing
- Improved adherence: Minimizes the necessity for frequent dosing, enhancing patient compliance for a more consistent approach to symptom management
- Safety Assurance: Formulated with ingredients known for their safety profile in pregnant women, ensuring a secure and reliable option for managing symptoms

Queezy-ER® is now available in leading pharmacies across India.

ABOUT JAGSONPAL PHARMACEUTICALS LIMITED

Jagsonpal Pharmaceuticals Limited is a Delhi-based pharmaceutical company. Founded in 1978, the Company has a proven track record of 40+ years of catering to the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynaecology and Orthopaedics segments. Over the years, the Company has successfully built multiple brands that today hold market-leading position in respective segments. It has created a niche for itself in these value-accretive segments with 17 brands amongst Top 5 brands in the molecule category. It has an extensive pan-India presence through its strong sales team of 900+ individuals.

For more information, please visit: www.jagsonpal.com

Ashish Lakhota

Chief Financial Officer, Jagsonpal Pharmaceuticals Limited

Contact: cs@jagsonpal.com, +91 124 4406710

CIN: L74899DL1978PLC009181

Registered Office: T-210 J, Shahpur Jat, New Delhi – 110049

Corporate Office: Nimai Tower, 3rd floor, Phase – IV, Udyog Vihar, Gurugram – 122015